Javascript must be enabled to continue!
rno‐miR‐90 promotes chondrogenic differentiation of bone marrow mesenchymal stem cells by targeting SPARC‐related modular calcium binding 2
View through CrossRef
AbstractBone marrow mesenchymal stem cells (BMSCs) have the ability to differentiate into chondrocytes. In the differentiation of BMSCs into chondrocytes, micro‐RNAs (miRNAs) play an important role. rno‐miR‐90 is a new miRNA discovered by our research team, and its role in chondrogenic differentiation of BMSCs is unknown. This study aimed to investigate whether rno‐miR‐90 could promote chondrogenic differentiation of BMSCs by regulating secreted protein acidic and rich in cysteine‐related modular calcium binding 2 (Smoc2). First, BMSCs chondroblast differentiation was successfully induced in vitro by classical induction method of transforming growth factor (TGF)‐β3. On this basis, we transfected rno‐miR‐90 mimic and inhibitor, and confirmed that rno‐miR‐90 mimic could promote the differentiation of BMSCs into chondrocytes by real‐time reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) and western blotting. In addition, we demonstrated that Smoc2 was a target gene of rno‐miR‐90 by dual‐luciferase reporter assay, and confirmed that rno‐miR‐90 mimic could inhibit the expression of Smoc2 by RT‐qPCR and western blotting. In order to further prove the targeting relationship between rno‐miR‐90 and Smoc2, we constructed three interfering fragments of Smoc2, and proved that silencing Smoc2 could promote the differentiation of BMSCs into chondrocytes at the transcriptional and protein levels. Finally, we constructed a carrier scaffold for ectopic chondrogenic differentiation in vivo, and confirmed that rno‐miR‐90 mimic and siSmoc2 could promote chondrogenic differentiation of BMSCs by Alcian blue staining and immunohistochemistry. In summary, our results suggested that rno‐miR‐90 could promote chondrogenic differentiation of BMSCs by down‐regulating the expression of Smoc2. rno‐miR‐90 mimic and Smoc2 may be therapeutic targets of osteoarthritis.
Title: rno‐miR‐90 promotes chondrogenic differentiation of bone marrow mesenchymal stem cells by targeting SPARC‐related modular calcium binding 2
Description:
AbstractBone marrow mesenchymal stem cells (BMSCs) have the ability to differentiate into chondrocytes.
In the differentiation of BMSCs into chondrocytes, micro‐RNAs (miRNAs) play an important role.
rno‐miR‐90 is a new miRNA discovered by our research team, and its role in chondrogenic differentiation of BMSCs is unknown.
This study aimed to investigate whether rno‐miR‐90 could promote chondrogenic differentiation of BMSCs by regulating secreted protein acidic and rich in cysteine‐related modular calcium binding 2 (Smoc2).
First, BMSCs chondroblast differentiation was successfully induced in vitro by classical induction method of transforming growth factor (TGF)‐β3.
On this basis, we transfected rno‐miR‐90 mimic and inhibitor, and confirmed that rno‐miR‐90 mimic could promote the differentiation of BMSCs into chondrocytes by real‐time reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) and western blotting.
In addition, we demonstrated that Smoc2 was a target gene of rno‐miR‐90 by dual‐luciferase reporter assay, and confirmed that rno‐miR‐90 mimic could inhibit the expression of Smoc2 by RT‐qPCR and western blotting.
In order to further prove the targeting relationship between rno‐miR‐90 and Smoc2, we constructed three interfering fragments of Smoc2, and proved that silencing Smoc2 could promote the differentiation of BMSCs into chondrocytes at the transcriptional and protein levels.
Finally, we constructed a carrier scaffold for ectopic chondrogenic differentiation in vivo, and confirmed that rno‐miR‐90 mimic and siSmoc2 could promote chondrogenic differentiation of BMSCs by Alcian blue staining and immunohistochemistry.
In summary, our results suggested that rno‐miR‐90 could promote chondrogenic differentiation of BMSCs by down‐regulating the expression of Smoc2.
rno‐miR‐90 mimic and Smoc2 may be therapeutic targets of osteoarthritis.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
GW24-e2497 Circulating MicroRNAs as Potential Biomarkers of Coagulation Dysfunction in Patients with Vulnerable Coronary Artery Disease
GW24-e2497 Circulating MicroRNAs as Potential Biomarkers of Coagulation Dysfunction in Patients with Vulnerable Coronary Artery Disease
Objectives
The activation of coagulation and fibrinolysis plays a critical role in the incidence of coronary events. MicroRNAs (miRNAs) are small non-coding ribon...
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
Abstract
Purpose
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and lacks specific targeted ...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Comprehensive ceRNA Network Analysis Reveals Regulatory Mechanisms of mRNA, miRNA, circRNA, and lncRNA in Methcathinone-Induced Neurotoxicity
Comprehensive ceRNA Network Analysis Reveals Regulatory Mechanisms of mRNA, miRNA, circRNA, and lncRNA in Methcathinone-Induced Neurotoxicity
Abstract
Methcathinone, a synthetic cathinone derivative similar to amphetamine, has raised public health concerns due to its addictive properties and health risks ...
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
618 Background: Neoadjuvant combinations of gemcitabine (G), anthracyclines and taxanes have demonstrated substantial activity with pCR rates of 20–25%. Secreted protein acidic ri...
Differential marker expression by cultures rich in mesenchymal stem cells
Differential marker expression by cultures rich in mesenchymal stem cells
AbstractBackgroundMesenchymal stem cells have properties that make them amenable to therapeutic use. However, the acceptance of mesenchymal stem cells in clinical practice requires...
Expression of microRNAs, miR‐21, miR‐31, miR‐122, miR‐145, miR‐146a, miR‐200c, miR‐221, miR‐222, and miR‐223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance
Expression of microRNAs, miR‐21, miR‐31, miR‐122, miR‐145, miR‐146a, miR‐200c, miR‐221, miR‐222, and miR‐223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance
AbstractMicroRNAs are a class of non‐coding molecules found to regulate a variety of cellular functions in health and disease. Dysregulation of microRNAs is involved in liver disea...

